Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018085521) NOVEL DOSAGE REGIMEN
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/085521 International Application No.: PCT/US2017/059691
Publication Date: 11.05.2018 International Filing Date: 02.11.2017
IPC:
A61K 31/401 (2006.01) ,A61P 25/02 (2006.01) ,A61P 29/00 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
40
having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
401
Proline; Derivatives thereof, e.g. captopril
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25
Drugs for disorders of the nervous system
02
for peripheral neuropathies
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
29
Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (NSAIDs)
Applicants:
BIOGEN INC. [US/US]; 225 Binney Street Cambridge, MA 02142, US
BIOGEN MA INC. [US/US]; 250 Binney Street Cambridge, MA 02142, US
Inventors:
MORISSET, Valerie; US
NAIK, Himanshu; US
DUNBAR, Joi; US
VERSAVEL, Mark; US
Agent:
HALSTEAD, David, P.; US
BLOUNT, Jennifer, V.; US
HALSTEAD, David, P.; US
ABELLEIRA, Susan, M.; US
AKHIEZER, Alexander; US
Priority Data:
62/416,39202.11.2016US
62/515,83606.06.2017US
Title (EN) NOVEL DOSAGE REGIMEN
(FR) NOUVEAU SCHÉMA POSOLOGIQUE
Abstract:
(EN) The present invention is directed to a novel method of treating a disease or condition mediated by modulation of Nav1.7 and other voltage-gated sodium channel subtypes, such as pain, in particular neuropathic pain, most particularly trigeminal neuralgia.
(FR) La présente invention concerne une nouvelle méthode de traitement d'une maladie ou d'un état médié par la modulation de Nav1.7 et d'autres sous-types de canaux sodiques voltage dépendants, tels que la douleur, en particulier la douleur neuropathique, et plus particulièrement la prosopalgie.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)